Soleno Therapeutics Inc
6XC
Company Profile
Business description
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Contact
100 Marine Parkway
Suite 400
Redwood CityCA94065
USAT: +1 650 213-8444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
152
Stocks News & Analysis
stocks
The trillion-dollar club: Are these mega-sized stocks still buys?
The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
stocks
New pricing model for embattled ASX tech leader
Investor day shows off potentially disruptive pricing model.
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
Shares trade at a discount despite attractive longer-term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.10 | 19.30 | 0.22% |
| CAC 40 | 8,116.75 | 5.28 | -0.07% |
| DAX 40 | 24,061.55 | 179.52 | 0.75% |
| Dow JONES (US) | 47,977.49 | 126.55 | 0.26% |
| FTSE 100 | 9,675.49 | 35.38 | -0.36% |
| HKSE | 26,085.08 | 149.18 | 0.58% |
| NASDAQ | 23,538.64 | 33.50 | 0.14% |
| Nikkei 225 | 50,491.87 | 536.55 | -1.05% |
| NZX 50 Index | 13,483.99 | 31.63 | -0.23% |
| S&P 500 | 6,871.30 | 14.18 | 0.21% |
| S&P/ASX 200 | 8,634.60 | 20.50 | 0.24% |
| SSE Composite Index | 3,902.81 | 27.01 | 0.70% |